PART I ITEM 1 - BUSINESS Overview We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need. We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-27 | 2025-12-31 | 0001566044-26-000002 | EDGAR | 89K words |
| 2025-03-06 | 2024-12-31 | 0001628280-25-010908 | EDGAR | — |
| 2024-03-01 | 2023-12-31 | 0001628280-24-008178 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0001628280-23-007900 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001628280-22-006545 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001566044-21-000010 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001564590-20-008442 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005451 | EDGAR | — |
| 2018-03-28 | 2017-12-31 | 0001628280-18-003726 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001566044-25-000010 | EDGAR | 29K words |
| 2025-08-14 | 2025-06-30 | 0001628280-25-040366 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023740 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001628280-24-046244 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001628280-24-037176 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001628280-24-022183 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001628280-23-038414 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001628280-23-029334 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001628280-23-017583 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001628280-22-029836 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001628280-22-022687 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001628280-22-014092 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001104659-26-026439 | EDGAR | 1K words |
| 2026-01-30 | 0001104659-26-008642 | EDGAR | — |
| 2025-12-17 | 0001104659-25-121828 | EDGAR | — |
| 2025-12-12 | 0001104659-25-120637 | EDGAR | — |
| 2025-11-06 | 0001566044-25-000007 | EDGAR | — |
| 2025-09-12 | 0001104659-25-089531 | EDGAR | — |
| 2025-08-14 | 0001104659-25-078135 | EDGAR | — |
| 2025-07-30 | 0001104659-25-071953 | EDGAR | — |
| 2025-05-08 | 0001628280-25-023478 | EDGAR | — |
| 2025-03-06 | 0001628280-25-010777 | EDGAR | — |
178 total filings indexed. 147 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001566044 |
| Ticker | VYNE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.vynetherapeutics.com |
| Listed | 2018-01-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report